Treatment of C3 Glomerulopathy with Complement Blockers

 

 Buy Article Permissions and Reprints

Abstract

C3 glomerulopathy (C3G) is a newly defined clinical entity comprising glomerular lesions with predominant C3 staining. Under this definition are now included membranoproliferative glomerulonephritis type II (dense deposit disease) and C3 glomerulonephritis. This group of glomerular diseases with a heterogeneous histological aspect shares a common pathogenesis, that is, a dysregulation of the alternative pathway of complement in the fluid phase leading to C3 deposition in the kidney. Recent advances have expanded our understanding of the underlying mechanisms, leading to the hypothesis that blocking the alternative complement pathway may be an effective treatment for C3Gs, as has been shown in other renal diseases driven by alternative pathway dysregulation, such as atypical hemolytic uremic syndrome. Results of 11 published cases of patients with different forms of C3G treated with eculizumab, an anti-C5 humanized monoclonal antibody, are encouraging. Given the complexity of disease pathogenesis in C3G, a patient-tailored approach including a comprehensive workup of complement abnormalities is necessary to evaluate the best treatment options. Clinical trials assessing effectiveness of different complement blockers on the background of the individual complement profile are needed.

• References

• 1 Pickering MC, D'Agati VD, Nester CM , et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84 (6) 1079-1089
  CrossrefPubMedGoogle Scholar
• 2 Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014; 40 (4) 416-421
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Xiao X, Pickering MC, Smith RJH. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. Semin Thromb Hemost 2014; 40 (4) 465-471
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 2012; 81 (5) 434-441
  CrossrefPubMedGoogle Scholar
• 5 Sethi S, Fervenza FC, Zhang Y , et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82 (4) 465-473
  CrossrefPubMedGoogle Scholar
• 6 Legendre CM, Licht C, Muus P , et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368 (23) 2169-2181
  CrossrefPubMedGoogle Scholar
• 7 Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V ; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8 (11) 643-657
  CrossrefPubMedGoogle Scholar
• 8 Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens 2013; 22 (2) 231-237
  CrossrefPubMedGoogle Scholar
• 9 Zhang Y, Nester CM, Holanda DG , et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol 2013; 24 (11) 1820-1829
  CrossrefPubMedGoogle Scholar
• 10 Medjeral-Thomas N, Malik TH, Patel MP , et al. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int 2014; 85 (4) 933-937
  CrossrefPubMedGoogle Scholar
• 11 Gale DP, de Jorge EG, Cook HT , et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376 (9743) 794-801
  CrossrefPubMedGoogle Scholar
• 12 Malik TH, Lavin PJ, Goicoechea de Jorge E , et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012; 23 (7) 1155-1160
  CrossrefPubMedGoogle Scholar
• 13 Vernon KA, Cook HT. Complement in glomerular disease. Adv Chronic Kidney Dis 2012; 19 (2) 84-92
  CrossrefPubMedGoogle Scholar
• 14 Hawfield A, Iskandar SS, Smith RJ. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy. Am J Kidney Dis 2013; 61 (5) 828-831
  CrossrefPubMedGoogle Scholar
• 15 Zipfel PF, Lauer N. Defective complement action and control defines disease pathology for retinal and renal disorders and provides a basis for new therapeutic approaches. Adv Exp Med Biol 2013; 735: 173-187
  PubMedGoogle Scholar
• 16 Servais A, Noël LH, Roumenina LT , et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82 (4) 454-464
  CrossrefPubMedGoogle Scholar
• 17 Pickering MC, Cook HT, Warren J , et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31 (4) 424-428
  PubMedGoogle Scholar
• 18 Pickering MC, Warren J, Rose KL , et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A 2006; 103 (25) 9649-9654
  CrossrefPubMedGoogle Scholar
• 19 Bomback AS, Smith RJ, Barile GR , et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7 (5) 748-756
  CrossrefPubMedGoogle Scholar
• 20 Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012; 366 (12) 1163-1165
  CrossrefPubMedGoogle Scholar
• 21 Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012; 366 (12) 1161-1163
  CrossrefPubMedGoogle Scholar
• 22 Radhakrishnan S, Lunn A, Kirschfink M , et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366 (12) 1165-1166
  CrossrefPubMedGoogle Scholar
• 23 McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012; 12 (4) 1046-1051
  CrossrefPubMedGoogle Scholar
• 24 Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 2013; 28 (10) 1975-1981
  CrossrefPubMedGoogle Scholar
• 25 Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs 2013; 73 (18) 2053-2066
  CrossrefPubMedGoogle Scholar
• 26 Nester CM, Brophy PD. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Curr Opin Pediatr 2013; 25 (2) 225-231
  CrossrefPubMedGoogle Scholar
• 27 Herlitz LC, Bomback AS, Markowitz GS , et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23 (7) 1229-1237
  CrossrefPubMedGoogle Scholar
• 28 Hong Y, Zhou W, Li K, Sacks SH. Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells. Kidney Int 2002; 62 (4) 1291-1300
  CrossrefPubMedGoogle Scholar
• 29 Wang J, Tang Z, Luo C , et al. Clinical and pathological features of dense deposit disease in Chinese patients. Clin Nephrol 2012; 78 (3) 207-215
  CrossrefPubMedGoogle Scholar
• 30 Appel GB, Cook HT, Hageman G , et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16 (5) 1392-1403
  CrossrefPubMedGoogle Scholar